U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H12N2O
Molecular Weight 236.2691
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARBAMAZEPINE

SMILES

c1ccc2c(c1)C=Cc3ccccc3N2C(=N)O

InChI

InChIKey=FFGPTBGBLSHEPO-UHFFFAOYSA-N
InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

HIDE SMILES / InChI

Molecular Formula C15H12N2O
Molecular Weight 236.2691
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/carbamazepine.html http://www.rxlist.com/carnexiv-drug.htm http://www.wikidoc.org/index.php/Carbamazepine

Carbamazepine is an analgesic, anti-epileptic agent that is FDA approved for the treatment of epilepsy, trigeminal neuralgia. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. It depresses thalamic potential and bulbar and polysynaptic reflexes, including the linguomandibular reflex in cats. Commonly reported side effects of carbamazepine include: dizziness, drowsiness, nausea, ataxia, and vomiting. Carbamazepine is a potent inducer of hepatic CYP1A2, 2B6, 2C9/19, and 3A4 and may reduce plasma concentrations of concomitant medications mainly metabolized by CYP1A2, 2B6, 2C9/19, and 3A4 through induction of their metabolism, like Boceprevir, Cyclophosphamide, Aripiprazole, Tacrolimus, Temsirolimus and others.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
152.0 µM [IC50]
25.0 µM [Ki]
Target ID: Q9NY46|||Q9Y6P4
Gene ID: 6328.0
Gene Symbol: SCN3A
Target Organism: Homo sapiens (Human)
16.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TEGRETOL

Approved Use

Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.

Launch Date

-5.7110401E10
Primary
TEGRETOL

Approved Use

Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.

Launch Date

-5.7110401E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.2 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARBAMAZEPINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
1.9 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARBAMAZEPINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
11 μg/mL
800 mg 2 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CARBAMAZEPINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
4.3 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARBAMAZEPINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: HIGH-FAT
3.2 μg/mL
1600 mg 1 times / day multiple, oral
dose: 1600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CARBAMAZEPINE-10,11-EPOXIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1.5 μg/mL
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CARBAMAZEPINE-10,11-EPOXIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.11 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARBAMAZEPINE-10,11-EPOXIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
2.2 μg/mL
800 mg 2 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CARBAMAZEPINE-10,11-EPOXIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
32.6 μg × h/mL
1600 mg 1 times / day multiple, oral
dose: 1600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CARBAMAZEPINE-10,11-EPOXIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
15.7 μg × h/mL
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CARBAMAZEPINE-10,11-EPOXIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
37.5 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARBAMAZEPINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
14.5 h
800 mg 2 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CARBAMAZEPINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
34 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARBAMAZEPINE-10,11-EPOXIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
24%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARBAMAZEPINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
50%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARBAMAZEPINE-10,11-EPOXIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg 2 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources: Page: p.1297
unhealthy, 73.1 ± 5.5
n = 91
Health Status: unhealthy
Condition: Epilepsy
Age Group: 73.1 ± 5.5
Sex: M+F
Population Size: 91
Sources: Page: p.1297
Disc. AE: Skin and subcutaneous conditions NEC, Fatigue...
AEs leading to
discontinuation/dose reduction:
Skin and subcutaneous conditions NEC (8.8%)
Fatigue
Somnolence
Sources: Page: p.1297
AEs

AEs

AESignificanceDosePopulation
Skin and subcutaneous conditions NEC 8.8%
Disc. AE
1000 mg 2 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources: Page: p.1297
unhealthy, 73.1 ± 5.5
n = 91
Health Status: unhealthy
Condition: Epilepsy
Age Group: 73.1 ± 5.5
Sex: M+F
Population Size: 91
Sources: Page: p.1297
Fatigue Disc. AE
1000 mg 2 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources: Page: p.1297
unhealthy, 73.1 ± 5.5
n = 91
Health Status: unhealthy
Condition: Epilepsy
Age Group: 73.1 ± 5.5
Sex: M+F
Population Size: 91
Sources: Page: p.1297
Somnolence Disc. AE
1000 mg 2 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources: Page: p.1297
unhealthy, 73.1 ± 5.5
n = 91
Health Status: unhealthy
Condition: Epilepsy
Age Group: 73.1 ± 5.5
Sex: M+F
Population Size: 91
Sources: Page: p.1297
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
strong
yes (co-administration study)
Comment: Midazolam plasma concentrations reduced dramatically in patients treated with carbamazepine and phenytoin; The CYP3A4-mediated metabolism of cyclosporin is markedly accelerated by carbamazepine comedication; Many other likely DDIs with carbamazepine. See https://pubmed.ncbi.nlm.nih.gov/8877250/
Page: 12.0
yes
yes
yes
yes
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
[Carbamazepine-induced hepatitis. A case report].
1999
[Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon].
1999 Jun
Carbamazepine-associated severe left ventricular dysfunction.
2000
Carbamazepine induced bradycardia.
2000 Dec
Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial.
2000 Dec
A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy.
2000 Feb
Phenytoin poisoning after using Chinese proprietary medicines.
2000 Jul
Potential interaction between ritonavir and carbamazepine.
2000 Jul
Reversible pitch perception deficit caused by carbamazepine.
2000 Jul-Aug
[A case of superior sagittal sinus thrombosis following long-term medication with carbamazepine].
2000 Jun
Carbamazepine-induced combined phonic and motor tic in a boy with Down's syndrome.
2000 Mar
Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy.
2000 May
Carbamazepine suppresses methamphetamine-induced Fos expression in a regionally specific manner in the rat brain. Possible neural substrates responsible for antimanic effects of mood stabilizers.
2000 May
Antiepileptic drug-induced visual hallucinations in a child.
2000 Nov
Renal tubular function in patients receiving anticonvulsant therapy: a long-term study.
2000 Nov
[Carbamazepine-induced hepatitis].
2000 Oct 10
[Two cases of auditory disturbance caused by carbamazepine].
2000 Sep
New developments in the pharmacotherapy of alcohol dependence.
2001
Update on anticonvulsants for the treatment of alcohol withdrawal.
2001
Investigation and medical management of trigeminal neuralgia by consultant oral and maxillofacial surgeons in the British Isles.
2001 Apr
Novel treatments for bipolar disorder.
2001 Apr
Comparison the cognitive effect of anti-epileptic drugs in seizure-free children with epilepsy before and after drug withdrawal.
2001 Apr
Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring.
2001 Feb
Functional changes and adverse reactions after successful treatment of hereditary myokymia: a case report.
2001 Feb
Recommendations for the management of behavioral and psychological symptoms of dementia.
2001 Feb
Anticonvulsant and sodium channel blocking activity of higher doses of clenbuterol.
2001 Feb
The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation.
2001 Feb
Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population.
2001 Feb
Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy.
2001 Feb
Significance of atypical presentation of symptomatic SUNCT: a case report.
2001 Feb
The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study.
2001 Feb
A model of atypical absence seizures: EEG, pharmacology, and developmental characterization.
2001 Feb 13
Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry.
2001 Feb 23
Seizures in multiple sclerosis.
2001 Jan
Effects of antiepileptic drugs on rat platelet aggregation: ex vivo and in vitro study.
2001 Jan
Interleukin-6 enhances expression of adenosine A(1) receptor mRNA and signaling in cultured rat cortical astrocytes and brain slices.
2001 Jan
Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy.
2001 Jan 9
Changes in color vision after a single dose of vigabatrin or carbamazepine in healthy volunteers.
2001 Jan-Feb
Mood stabilizers and ion regulation.
2001 Jan-Feb
Taking the sting out of trigeminal neuralgia.
2001 Mar
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
2001 Mar
Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice.
2001 Mar
Treatment of bipolar affective disorder in clinical practice.
2001 Mar
Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms.
2001 Mar
Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients.
2001 Mar
Suppressive effects of oxcarbazepine on tooth pulp-evoked potentials recorded at the trigeminal spinal tract nucleus in cats.
2001 Mar
The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities.
2001 Mar 14
Carbamazepine prevents imipramine-induced behavioural sensitization to the dopamine D(2)-like receptor agonist quinpirole.
2001 Mar 23
Separation of olanzapine, carbamazepine and their main metabolites by capillary electrophoresis with pseudo-stationary phases.
2001 Mar 5
New anticonvulsants for use in pediatric patients (part I).
2001 Mar-Apr
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: The total daily dose of CARNEXIV is 70% of the total daily oral carbamazepine dose from which patients are being switched. The total daily dose of CARNEXIV should be equally divided in four 30-minute infusions, separated by 6 hours.
Initial Dose: 400 mg per day. Subsequent Dose: add up to 200 mg per day at weekly intervals. Maximum daily dose is 1600 mg
Route of Administration: Other
Human liver microsomes (HLMs) converted carbamazepine (30-300 microM) to 3-hydroxycarbamazepine at rates >25 times those of 2-hydroxycarbamazepine. Rates of carbamazepine 2- and 3-hydroxylation correlated strongly with CYP2B6 activity (r >or= 0.757) in a panel of HLMs (n = 8). Carbamazepine 3-hydroxylation also correlated significantly with CYP2C8 activity at a carbamazepine concentration of 30 microM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:53:44 UTC 2021
Edited
by admin
on Fri Jun 25 20:53:44 UTC 2021
Record UNII
33CM23913M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARBAMAZEPINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RC   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
CARBAMAZEPINE [USP-RC]
Common Name English
EQUETRO
Brand Name English
TERIL
Brand Name English
NEUROTOP
Common Name English
KARBAMAZEPIN
Common Name English
CARBAMAZEPINE [INN]
Common Name English
CARBAMAZEPINE [WHO-DD]
Common Name English
OXCARBAZEPINE IMPURITY A [EP]
Common Name English
G-32883
Code English
5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE
Systematic Name English
CARBAMAZEPINE [WHO-IP]
Common Name English
TEGRETOL
Brand Name English
NEUROTOL
Common Name English
CARBAMAZEPINE [VANDF]
Common Name English
NSC-169864
Code English
SIRTAL
Brand Name English
FINLEPSIN
Brand Name English
CARBAMAZEPINE [ORANGE BOOK]
Common Name English
EPITOL
Brand Name English
CARBAMAZEPINE [EP MONOGRAPH]
Common Name English
STAZEPINE
Brand Name English
CARBAMAZEPINE [USAN]
Common Name English
CARBAMAZEPINE [MART.]
Common Name English
CARBAMAZEPINE EXTENDED RELEASE
Common Name English
BISTON
Brand Name English
TELESMIN
Brand Name English
GEIGY 32883
Code English
CARBAMAZEPINE [MI]
Common Name English
CARBATROL
Brand Name English
CARBAMAZEPINE [HSDB]
Common Name English
TIMONIL
Brand Name English
CARBAMAZEPINE ANHYDROUS
Common Name English
KARBELEX
Common Name English
TEGRETAL
Brand Name English
CARBAMAZEPINE [USP-RS]
Common Name English
CARBAMAZEPINE [USP MONOGRAPH]
Common Name English
CARBAMAZEPINUM [WHO-IP LATIN]
Common Name English
CARBAMAZEPINE [USP]
Common Name English
CARNEXIV
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C264
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
NDF-RT N0000008486
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
NDF-RT N0000175753
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 24.2.2
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
NDF-RT N0000175751
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
FDA ORPHAN DRUG 43590
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
FDA ORPHAN DRUG 265508
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
WHO-ATC N03AF01
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
LIVERTOX 146
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
WHO-VATC QN03AF01
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
EU-Orphan Drug EU/3/16/1746
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 05
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
Code System Code Type Description
EVMPD
SUB06113MIG
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
LACTMED
Carbamazepine
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
EPA CompTox
298-46-4
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
CAS
298-46-4
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
HSDB
3019
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
ECHA (EC/EINECS)
206-062-7
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
WIKIPEDIA
CARBAMAZEPINE
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
ChEMBL
CHEMBL108
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
FDA UNII
33CM23913M
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
NDF-RT
N0000191266
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY Cytochrome P450 1A2 Inducers [MoA]
USP_CATALOG
1093001
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY USP-RS
PUBCHEM
2554
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
MERCK INDEX
M3053
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY Merck Index
RXCUI
2002
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
489
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
DRUG BANK
DB00564
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
INN
1836
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
NCI_THESAURUS
C341
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
NDF-RT
N0000185607
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY Cytochrome P450 2C19 Inducers [MoA]
MESH
D002220
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CARBAMAZEPINE
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY Description: A white to yellowish white, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water and ether R; soluble in ethanol (~750 g/l) TS. Category: Antiepileptic drug. Storage: Carbamazepine should be kept in a tightly closed container. Definition: Carbamazepine contains not less than 98.0% and not more than 102.0% of C15H12N2O, calculated with reference to the dried substance.
NDF-RT
N0000187064
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY Cytochrome P450 2B6 Inducers [MoA]
NDF-RT
N0000185507
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY Cytochrome P450 2C9 Inducers [MoA]
IUPHAR
5339
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY
NDF-RT
N0000185506
Created by admin on Fri Jun 25 20:53:44 UTC 2021 , Edited by admin on Fri Jun 25 20:53:44 UTC 2021
PRIMARY Cytochrome P450 3A4 Inducers [MoA]
Related Record Type Details
METABOLIC ENZYME -> INDUCER
POTENT
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
TRANSPORTER -> INDUCER
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
METABOLIC ENZYME -> INDUCER
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
PARENT -> IMPURITY
UNSPECIFIED
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC